In the News: July 18–July 25
Invest in Primary Care to Achieve Scale, Better Patient Outcomes
A recent FierceHealthcare article discusses the results of a Patient-Centered Primary Care Collaborative (PCPCC) analysis emphasizing the importance of investing in primary care to improve patient outcomes. The PCPCC report found when primary care spending is higher, better patient outcomes were observed, including decrease in hospitalizations and ED visits. Although rates are low across the nation, more and more states are increasingly introducing legislation to track and increase primary care spending.
Sg2 believes investing in primary care to scale the primary care ecosystem across multiple access channels is key, as new low-acuity access channels appear and consumer expectations grow. To learn more about how one organization ensured its patients’ seamless access to low-acuity care sites and leveraged consumer data and segmentation to inform its strategies, register for the Sg2 Webinar Primary Care Network: Achieving Scale.
Potential Blood Test for Alzheimer Disease Seems Within Reach
A recent Modern Healthcare article suggests screening individuals for Alzheimer disease and dementia through blood tests may soon become the new norm. Numerous research groups presented new results regarding different tests they have in development. One experimental test measures abnormal variations of the protein known to form plaques in the brain, which is the hallmark symptom of Alzheimer disease. The blood test results closely match the results of the top tests currently being used, including brain scans and cognitive assessments. The test correctly identified 92% of people who had Alzheimer disease and correctly ruled out 85% who did not, for an overall accuracy of 88%.
Currently, 50 million people have dementia, with Alzheimer disease being the most common type. As of now, there is no cure, and current treatments just temporarily subdue symptoms. The current diagnostic tools (eg, brain scans, spinal fluid tests) are too expensive or too impractical to be formed at regular checkups, further incentivizing the ease and cost of a blood test that may also improve diagnosis time.
In combination with alternative care delivery models, improvements in both diagnosis and treatment may strengthen connectivity along the entire care pathway as it relates to Alzheimer disease. For more on the outlook for Alzheimer disease and dementia care, as well as how focusing on earlier prevention and diagnosis innovations may change the future of the disease, read the Sg2 FAQ Alzheimer and Dementia Care Landscape.